Linda S Chang

US Patent:

6420418, Jul 16, 2002

Filed:

Aug 14, 2000

Appl. No.:

09/638074

Inventors:

William K. Hagmann - Westfield NJ
Stephen E. Delaszlo - Rumson NJ
George Doherty - Princeton NJ
Linda L. Chang - Wayne NJ
Ginger X. Yang - Jersey City NJ

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 3134

US Classification:

514471, 514470, 514465, 549322, 549484

Abstract:

Compounds of Formula I are antagonists of VLA-4 and/or 47, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimers disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohns disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

US Patent:

6559174, May 6, 2003

Filed:

Mar 13, 2002

Appl. No.:

10/097028

Inventors:

Linus S. Lin - Westfield NJ
Shrenik K. Shah - Metuchen NJ
Linda L. Chang - Wayne NJ
William K. Hagmann - Westfield NJ
Richard A. Mumford - Red Bank NJ

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 3147

US Classification:

514406, 514303, 514309, 514338, 514339, 514416, 546120, 546141, 5462757, 5462771, 5483605, 548482

Abstract:

Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimers disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohns disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

US Patent:

6855708, Feb 15, 2005

Filed:

Mar 13, 2002

Appl. No.:

10/096607

Inventors:

Linus S. Lin - Westfield NJ, US
George Doherty - Princeton NJ, US
Shrenik K. Shah - Metuchen NJ, US
Linda L. Chang - Wayne NJ, US
William K. Hagmann - Westfield NJ, US
Richard A. Mumford - Red Bank NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K031/55
A61K031/47

US Classification:

51421701, 514241, 514309, 514406, 540593, 546120, 546141

Abstract:

Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

US Patent:

6972295, Dec 6, 2005

Filed:

Mar 12, 2003

Appl. No.:

10/387265

Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Shrenik K. Shah - Metuchen NJ, US
Ravindra N. Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda L. Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen M. Armstrong - Westfield NJ, US
James P. Jewell - Jersey City NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K031/4412
C07D213/70

US Classification:

514345, 546290

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

7550489, Jun 23, 2009

Filed:

Feb 1, 2008

Appl. No.:

12/012463

Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Shrenik K. Shah - Metuchen NJ, US
Ravindra N. Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda L. Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen M. Armstrong - Westfield NJ, US
James P. Jewell - Jersey City NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/435

US Classification:

514354, 514355

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

7629467, Dec 8, 2009

Filed:

Jul 20, 2004

Appl. No.:

10/565604

Inventors:

Lin Chu - Scotch Plains NJ, US
Mark T. Goulet - Westfield NJ, US
Feroze Ujjainwalla - Scotch Plains NJ, US
Linda Chang - Wayne NJ, US
Richard Frenette - Laval, CA
Yves Girard - Ile-Bizard, CA
Michel Therien - Laval, CA
Dwight Macdonald - L'lle-Bizard, CA
John H. Hutchinson - LaJolla CA, US

Assignee:

Merck & Co., Inc. - Rahway NJ
Merck Frosst Canada Ltd - Quebec

International Classification:

C07D 215/06
C07D 215/12
C07D 215/16
A61K 31/4375

US Classification:

546152, 514311

Abstract:

The instant invention provides compounds of formula: (I) which are 5-lipoxygenase activating protein inhibitors: formula (I). Compounds of formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cyto-protective agents.

US Patent:

7816534, Oct 19, 2010

Filed:

Apr 16, 2009

Appl. No.:

12/386336

Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Shrenik K. Shah - Metuchen NJ, US
Ravindra N. Guthikonda - Edison NJ, US
Hongbo Qi - Edison NJ, US
Linda L. Chang - Wayne NJ, US
Ping Liu - Edison NJ, US
Helen M. Armstrong - Westfield NJ, US
James P. Jewell - Jersey City NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/44
C07D 213/04
C07D 401/02
C07D 403/02
C07D 239/02

US Classification:

546255, 546266, 5462681, 544238, 514256, 514336, 514340

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

8153626, Apr 10, 2012

Filed:

Dec 7, 2007

Appl. No.:

12/517836

Inventors:

Robert K. Baker - Cranford NJ, US
Linda L. Chang - Wayne NJ, US
Marc Chioda - Metuchen NJ, US
Harry R. Chobanian - Aberdeen NJ, US
Yan Guo - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Kathleen M. Rupprecht - Cranford NJ, US
Shouwu Miao - Edison NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A01N 43/62
A61K 31/55
C07D 491/00
C07D 513/00
C07D 515/00
C07D 243/10
C07D 487/12

US Classification:

514220, 540557

Abstract:

Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.